Font Size:
Site Colors:
Accesskey
S - Skip navigation
1 - Home page
4 - Search
Accessibility Statement
Contact us
Find a Researcher

Oxidative Stress and human diseases

Dr. Soliman Khatib

97246953546
9726944980
Contact Dr. Soliman Khatib
  1. Identifying volatile organic compounds (VOCs) in blood as markers for early detection of various diseases including Parkinson's disease and other neurodegenerative disorders. Diseases are characterized by metabolism that releases volatile molecules to the blood, and to the lungs, from which some are released via exhalation. In this research we identify volatile molecules in the blood that are specific to various diseases such as Parkinson's disease and other neurodegenerative diseases, using solid phase microextraction (SPME), connected to a gas chromatography-mass spectroscopy (GC-MS) analyzer. This research was conducted in cooperation with Prof. John Finberg from the Faculty of Medicine and Prof. Hossam Heick from the Faculty of Chemical Engineering, both at the Technion, and funded by the MAGNET Directorate at the Office of the Chief Scientist of the Israeli Ministry of Industry, Trade and Labor. Recently we received a budget of 120,000 NIS from the Galilee Biomedical Research Administration for a period of two years (2015-2016), for the purpose of finding volatile molecules to act as biomarkers for the identification of early-stage Schizophrenia. The research is being conducted with the full cooperation of Dr. Alon Shamir from the Mazra Mental Health Center.

 

  1. Binding endogenous molecules to proteins to change their immunological properties. In this research different endogenous molecules were covalently connected to the protein surface, using different chemical methods, in order to change properties of the proteins, such as stability, activity and immunogenesis. The research is being conducted in cooperation with Prof. Jacob Pitcovski and Dr. Elina Aizenshtein, of MIGAL, and funded by the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor; a number of papers have been published summarizing this subject.
  2. Studying the effect of covalent and non-covalent modifications protein properties. The proteins change their physical and biological properties due to these modifications and their covalent and non-covalent chemical interactions with the small molecules in their environment. This property of proteins that developed during the process of evolution increases proteome diversity between 10- and 100-fold. The aim of the project is to choose proteins related to atherosclerosis, such as PON1, CETP, APO-A1 and APO-B, and to examine how their biological and physical properties are affected by modifications that may take place within the body such as acetylation, methylation, cysteinylation, glutathionylation, oxidation, nitrosylation etc.
  3. Production of food additives with health benefits from various kinds of algae. In this research we made extracts from different types of algae by using different types of solvents. We assessed the lipid composition of each extract and its concentration of Omega-3 fatty acids. We are currently assessing the anti-oxidative activity of each extract, using conventional methods, in order to determine their potential for use as food additives. We are also assessing the effect of the different extracts on components linked to atherosclerosis, such as macrophage cells, PON1, HDL and LDL, including isolation, characterization and identification of the active components. This research is being conducted in cooperation with Emma Kvitnitsky with a three-year grant (2013-2015) from the Kamin Program of the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor.
  4. Reducing CVD risk by using agents that improve HDL quality. High density lipoprotein HDL has a central role in atherosclerosis inhibition due to its antiatherogenic properties such as, reverse cholesterol transport (RCT), antioxidant, anti-inflammatory, anti-apoptotic, vasodilatory and cytoprotective effects, and endothelial function improvement. In the last several years, there is growing evidence from epidemiological data, animal studies, and clinical trials supports HDL as the next target to reduce residual cardiovascular risk in statin-treated, high-risk patients. However, some findings have called into question the hypothesis that pharmacologic increases in HDL cholesterol levels are necessarily beneficial. our strategy will be focus on improving HDL functions (HDL “quality”) which are truly reflect and responsible for the actual beneficial effects of HDL rather than on increasing  HDL-C levels (HDL-C “quantity”) by using natural agents isolated from micro-algae and other natural plants.

  5. CV

  6.  

Education

1993-1995       B.Sc., Ben-GurionUniversity, Department of Chemistry

1996-2000   Ph.D. (direct Ph.D. program), Technion – Israel Institute of Technology, Department ofChemistry

Academic and research positions

2001    Lecturer, Tel-Hai College, Department of Biotechnology

2008    Senior lecturer, Tel-Hai College, Department of Biotechnology

2001-present   Associate Researcher, The Oxidative Stress Research Laboratory, Migal – Galilee Research Institute.

Membership in professional organizations

2002-present   Israel Society for Oxygen and Free Radicals Research  

2002-present   Israeli Society for Research, Prevention and Treatment of Atherosclerosis

Research grants

2004-2007       Israeli Science Foundation – The search for natural substrates of paraoxonase. $65,000 per year. With prof. Jacob vaya.

2004-2005       D-Cure – The effect of  PON1 on early advances glycation products. $54,000 per year. With prof. Jacob Vaya and prof. Michael Aviram.

2006                Ministry of Industry and Commerce, Chief Scientist – Screening of protein surfaces for decreased antigenicity. $130,000. With prof. Jacob Vaya and prof. Jacob Pitcovski.

2007                (tashtiot) Ministry of Industry and Commerce, Chief Scientist –Screening of protein surfaces for decreased antigenicity. $150,000. With prof. Jacob Vaya and prof. Jacob Pitcovski.

2007                (tashtiot) Ministry of Industry and Commerce, Chief Scientist –Enhancing the immune response and development of conjugated vaccine administrated through non-injected route. $140,000. With prof. Jacob Vaya and prof. Jacob Pitcovski.

2008                (tashtiot) Ministry of Industry and Commerce, Chief Scientist – Screening of protein surfaces for decreased antigenicity. $300,000. With prof. Jacob Vaya and prof. Jacob Pitcovski.

2013                Chief Scientist Office of Israel-MAGNET – New artificial NOSE (Na-NOSE) for early detection of Parkinson's disease. 129,250 NIS. With prof. Jacob Vaya, prof. John Finberg and prof. Hossam Hieck.

2014                Chief Scientist Office of Israel-MAGNET – New artificial NOSE (Na-NOSE) for early detection of Parkinson's disease. 150,368 NIS. With prof. Jacob Vaya, prof. John Finberg and prof. Hossam Hieck.

2010-2013       Ministry of Industry and Commerce, Israel – Chicken vaccination at day one.  $200,000 per year. With Dr. Elina Aizenshtein.

2015-2016       The Galilee Biomedical Research Administration, Identification of volatile organic biomarkers in blood of patients with schizophrenia, 120,000 NIS for two years. With Dr. Alon Shamir from Mazra Mental Health Center and Prof. Jacob Vaya from Migal.

2015                Chief Scientist Office of Israel-ministry of economy, Development of biologically active substances from micro-algae extracts. 397,000 NIS for one year. With Prof. Jacob Vaya and Emma Kabtinski from migal.

 

Selected Publications

Oxysterols and symptomatic versus asymptomatic human atherosclerotic plaque

Biochemical and Biophysical Research Communications 2014 S. Khatib; J. Vaya Read online

The synthesis and analysis of S-nitorsylated paraoxonase 1

Biochem Biophys Res Commun 2014 Volume 444 Pages 354-359 Khatib S, Artoul F, Gershko M, Markman G, Vaya J. Read online

Analysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson’s disease

Neurochemistry International 2014 Volume 76 Pages 82-90 S. Khatib, J.P.M. Finberg, F. Artoul, Y. Lavner, S. Mahmood, U. Tisch, H. Haick, Y. Aluf, J. Vaya Read online

The effects and mechanism of flavonoid-rePON1 interactions. Structure-activity relationship study

Bioorganic and Medicinal Chemistry 2013 Volume 21 Issue 11 Pages 3348-3355 D. Atrahimovich; J. Vaya; S. Khatib Read online

Glabridin protects paraoxonase 1 from linoleic acid hydroperoxide inhibition via specific interaction: A fluorescence-quenching study

Journal of Agricultural and Food Chemistry 2012 Volume 60 Issue 14 Pages 3679-3685 D. Atrahimovich; J. Vaya; H. Tavori; S. Khatib Read online

Students

Post-graduate and post-doctoral research training

Researchers

Laboratories and research projects

Business

Business opportunities and technology transfer